Sorrento Therapeutics (SRNE), Yuhan Corp. Report Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
Tweet Send to a Friend
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) and Yuhan Corporation announced today that ImmuneOncia, a joint venture formed in September 2016, has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
